Altered Glycosylation of PSA in Prostate Cancer Tissue.

IF 2.5 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Prostate Pub Date : 2025-10-01 Epub Date: 2025-07-09 DOI:10.1002/pros.70014

Hannu Koistinen, Ruusu-Maaria Merivirta, Timo-Pekka Lehto, Anna Lempiäinen, Andrew Erickson, Ulf-Håkan Stenman, Antti Rannikko, Tuomas Mirtti

{"title":"Altered Glycosylation of PSA in Prostate Cancer Tissue.","authors":"Hannu Koistinen, Ruusu-Maaria Merivirta, Timo-Pekka Lehto, Anna Lempiäinen, Andrew Erickson, Ulf-Håkan Stenman, Antti Rannikko, Tuomas Mirtti","doi":"10.1002/pros.70014","DOIUrl":null,"url":null,"abstract":"Background: The glycosylation of proteins is commonly altered in cancer. This offers novel opportunities for cancer biomarker development. As prostate-specific antigen (PSA) is a glycoprotein, identification of cancer-specific PSA-glycoforms is feasible. Such PSA-glycoforms may provide valuable diagnostic and prognostic information.Methods: PSA-glycoforms were studied in tissues, using in situ proximity-ligation assay (PLA)-based detection with a PSA-specific antibody and 25 different glycan-binding lectins.Results: Using 25 different lectins and a small tissue microarray (TMA), we showed that glycosylation of PSA in cancerous tissues is different from that in benign prostate. In a larger TMA with samples from 162 patients, PSA-glycoforms detected by succinylated wheat germ (WGAsucc) and Vicia villosa (VVA) lectins were enriched in cancerous tissues as compared to adjacent benign tissues from the same patients (p < 10-4 for both, Kruskal-Wallis H test), although strong total PSA staining was more often found in benign tissues (p = 6*10-14).Conclusions: We showed here that glycosylation of PSA is changed in situ in prostate cancer. The identified lectins, showing preferential binding to cancer-associated PSA-glycoforms, will aid the future development of a diagnostic serum test of prostate cancer. Such a test has potential to revolutionize prostate cancer diagnostics.","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1290-1298"},"PeriodicalIF":2.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379856/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pros.70014","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The glycosylation of proteins is commonly altered in cancer. This offers novel opportunities for cancer biomarker development. As prostate-specific antigen (PSA) is a glycoprotein, identification of cancer-specific PSA-glycoforms is feasible. Such PSA-glycoforms may provide valuable diagnostic and prognostic information.

Methods: PSA-glycoforms were studied in tissues, using in situ proximity-ligation assay (PLA)-based detection with a PSA-specific antibody and 25 different glycan-binding lectins.

Results: Using 25 different lectins and a small tissue microarray (TMA), we showed that glycosylation of PSA in cancerous tissues is different from that in benign prostate. In a larger TMA with samples from 162 patients, PSA-glycoforms detected by succinylated wheat germ (WGA_succ) and Vicia villosa (VVA) lectins were enriched in cancerous tissues as compared to adjacent benign tissues from the same patients (p < 10^-4 for both, Kruskal-Wallis H test), although strong total PSA staining was more often found in benign tissues (p = 6*10^-14).

Conclusions: We showed here that glycosylation of PSA is changed in situ in prostate cancer. The identified lectins, showing preferential binding to cancer-associated PSA-glycoforms, will aid the future development of a diagnostic serum test of prostate cancer. Such a test has potential to revolutionize prostate cancer diagnostics.

Abstract Image

查看原文本刊更多论文

前列腺癌组织中PSA糖基化改变。

背景：蛋白质的糖基化通常在癌症中发生改变。这为癌症生物标志物的开发提供了新的机会。由于前列腺特异性抗原（PSA）是一种糖蛋白，因此鉴定癌症特异性PSA糖型是可行的。这种psa -糖型可能提供有价值的诊断和预后信息。方法：采用基于原位邻近结扎法（PLA）的psa特异性抗体和25种不同的聚糖结合凝集素检测组织中psa糖型。结果：使用25种不同的凝集素和小组织微阵列（TMA），我们发现癌组织中PSA的糖基化与良性前列腺不同。在162例患者的大样本TMA中，与来自同一患者的相邻良性组织相比，通过succinylated wheat germ （WGAsucc）和Vicia villosa （VVA）凝集素检测到的PSA-糖型在癌组织中富集（Kruskal-Wallis H试验，两者的p值均为-4），尽管在良性组织中更常发现强总PSA染色（p = 6*10-14）。结论：我们发现前列腺癌中PSA的糖基化发生了原位改变。所鉴定的凝集素，显示出与癌症相关的psa -糖型的优先结合，将有助于前列腺癌诊断血清测试的未来发展。这种测试有可能彻底改变前列腺癌的诊断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate 医学-泌尿学与肾脏学

CiteScore

5.10

自引率

3.60%

发文量

180

审稿时长

1.5 months

期刊介绍： The Prostate is a peer-reviewed journal dedicated to original studies of this organ and the male accessory glands. It serves as an international medium for these studies, presenting comprehensive coverage of clinical, anatomic, embryologic, physiologic, endocrinologic, and biochemical studies.